EVG.L Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (23 Apr 2024 @ 11:26):

Evgen Pharma plc, a clinical stage drug development company, focuses on the development of sulforaphane-based medicines for the treatment of cancer and inflammatory diseases...

Stats
Today's Volume	2.61M
Average Volume	1.54M
Market Cap	3.42M
EPS	£0 ( 2024-04-19 )
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	-0.800
ATR14	£0 (0.00%)

Evgen Pharma PLC Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Evgen Pharma PLC Financials

Annual	2022
Revenue:	£442 000
Gross Profit:	£429 000 (97.06 %)
EPS:	£-0.0147

Q2	2023
Revenue:	£396 000
Gross Profit:	£390 000 (98.48 %)
EPS:	£-0.00530

Q1	2023
Revenue:	£198 000
Gross Profit:	£-729 500 (-368.43 %)
EPS:	£-0.00270

Q4	2022
Revenue:	£442 000
Gross Profit:	£436 000 (98.64 %)
EPS:	£-0.00690

Financial Reports:

No articles found.

Evgen Pharma PLC

Evgen Pharma plc, a clinical stage drug development company, focuses on the development of sulforaphane-based medicines for the treatment of cancer and inflammatory diseases. It develops its products using Sulforadex, a sulforaphane stabilization technology. The company's lead product is SFX-01, that is in Phase II clinical trials for the treatment of metastatic breast cancer; and in Phase Ib/IIa clinical trials for the treatment of glioblastoma, as well as in preclinical stage for the treatment of haematological malignancies and analogues. It also provides out-licensing of its technology services. Evgen Pharma plc was incorporated in 2014 and is headquartered in Nether Alderley, the United Kingdom.